Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Efficacy of metoprolol succinate plus trimetazidine in the management of angina pectoris in coronary artery disease

Na Zhang, Yuanyuan Ren, Changliang Zhao

Cardiovascular Department, The Third Affiliated Hospital of Qiqihar Medical University, No. 27 Taishun Street, Tiefeng District, Qiqihar City, Heilongjiang Province, China;

For correspondence:- Changliang Zhao Email: zhaochangliang25@hotmail.com

Accepted: 30 May 2023 Published: 30 June 2023

Citation: Zhang N, Ren Y, Zhao C. Efficacy of metoprolol succinate plus trimetazidine in the management of angina pectoris in coronary artery disease. Trop J Pharm Res 2023; 22(6):1341-1347 doi: 10.4314/tjpr.v22i6.26

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy of metoprolol succinate (MET) plus trimetazidine (TMZ) in the management of angina pectoris in coronary artery disease.

Methods: A total of 94 patients with coronary angina were assigned equally to study group (received MET plus TMZ in addition to conventional symptomatic treatment) and control group (received conventional symptomatic treatment such as statins, nitrates, and aspirin). Heart rate was measured by a pulse oximeter, while angina attacks were measured by electrocardiogram (ECG). Left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF), and left ventricular posterior wall end diastole (LVPWD) were measured by cardiac ultrasound. Enzyme-linked immunosorbent assay (ELISA) was used to determine the concentration of hypersensitive C-reactive protein (hs-CRP). Adverse reactions were self-reported.

Results: MET plus TMZ group produced significantly higher treatment responses for patients (95.74 %) than control group which received conventional medication (80.85 %, p < 0.05). Patients exhibited a significantly lower heart rate, fewer angina attacks, and a shorter duration of attacks after administration of MET plus TMZ compared to conventional medication (p < 0.05). MET plus TMZ treatment resulted in significantly higher LVEF, shorter LVEDD, and LVPWD than conventional treatment (p < 0.05). The study group exhibited a significantly milder inflammatory response indicated by lower serum hypersensitive C-reactive protein (hs-CRP) concentrations, and lower incidence of adverse events (4.26 %) compared to control group (17.02 %, p < 0.05).

Conclusion: MET plus TMZ provides significant treatment benefits for patients with angina pectoris in coronary artery disease, mitigates clinical symptoms and inflammatory responses, enhances cardiac function, and improves treatment safety by reducing risk of adverse events.

Keywords: Metoprolol succinate, Trimetazidine, Coronary artery disease, Angina pectoris, Inflammatory response, C-reactive protein (hs-CRP), Adverse events